Although both genetic and epigenetic factors contribute to drug resistance, the intricacies of the interplay between the two groups of mechanisms and their control of plasticity and tumor heterogeneity in BRAF-mutant cancers remains to be fully elucidated. This evidence concerns the gene BRAF and neoplasm.